<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00963313</url>
  </required_header>
  <id_info>
    <org_study_id>SUE-ADA-2009-01</org_study_id>
    <nct_id>NCT00963313</nct_id>
  </id_info>
  <brief_title>A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis</brief_title>
  <official_title>A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. FRANCISCO J. BLANCO-GARCIA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigacion Biomedica de A Coruna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on published data and according to the approved product label for ankylosing
      spondylitis and psoriatic arthritis, it can be expected that adalimumab 40 mg every 14 days
      should be effective in psoriatic arthritic patients with axial involvement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A recent review from GRAPPA group evaluates therapies for PsA including peripheral and axPsA.
      Analysing particularly the results with present biologic therapies it has been proven that
      outcome data at 24 weeks show excellent results in the treatment of peripheral forms of PsA
      with either of the three biologics disposable in the market, that is to say infliximab,
      etanercept and adalimumab.

      However when it comes to analyse data on PsA patients with axPsA there are not results at
      all. The design of clinical trials did not evaluate axial outcomes and therefore there is not
      a possibility of knowing whether these therapies are useful in axPsA.

      This is an open label multicenter study designed to evaluate the effectivity of adalimumab 40
      mg every 2 weeks during 24 weeks in patients with active axial PsA despite receiving
      Methotrexate, Sulfasalazine, Leflunomide or Cyclosporine, plus NSAIDs and no more than 10 mg
      of corticosteroids.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>BASDAI score (Bath Ankylosing Spondylitis Disease Activity Index).</measure>
    <time_frame>12 WEEKS</time_frame>
    <description>Proportion of patients that reach a BASDAI 50% at week 12, BASDAI 50% means an improvement from baseline of 50% or an improvement of two units on a 10 unit scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with new adverse events.</measure>
    <time_frame>24 WEEKS</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ASAS 40 score.</measure>
    <time_frame>24 WEEKS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASAS 50 and ASAS 70 score, 5/6.</measure>
    <time_frame>12 WEEKS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of enthesitis.</measure>
    <time_frame>24 WEEKS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral articulation measured with DAS 28.</measure>
    <time_frame>24 WEEKS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of extraarticular manifestations.</measure>
    <time_frame>24 WEEKS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of laboratory parameters.</measure>
    <time_frame>24 WEEKS</time_frame>
    <description>Hematology, biochemistry, CRP, ESR, HLA-B27 and rheumatoid factor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of quality of life.</measure>
    <time_frame>24 WEEKS</time_frame>
    <description>SF36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of PASI (Psoriasis Area and Severity Index).</measure>
    <time_frame>24 WEEKS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of Modified NAPSI (Modified Nail Psoriasis Severity Index).</measure>
    <time_frame>24 WEEKS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of BASFI (Bath Ankylosing Spondylitis Functioning Index).</measure>
    <time_frame>24 WEEKS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of health.</measure>
    <time_frame>24 WEEKS</time_frame>
    <description>HAQ (Health Assessment Questionarie).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of dactylitis.</measure>
    <time_frame>24 WEEKS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of inflammatory biomarkers (IL6 and MMP3).</measure>
    <time_frame>24 WEEKS</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">29</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Adalimumab, injection</arm_group_label>
    <description>Adalimumab, one injection every fourteen days during 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab (HUMIRA®)</intervention_name>
    <description>Prefilled syringes containing 40 mg Adalimumab in 0.8 ml injection solution. Study drug will be subcutaneously self-administered every 2 weeks during 24 weeks.</description>
    <arm_group_label>Adalimumab, injection</arm_group_label>
    <other_name>HUMIRA®</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples recollected for analysing IL6 and MMP3 from patients blood serum.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with active axial forms of psoriatic arthritis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged between 18 and 70 years.

          -  A negative pregnancy test for women of childbearing potential during the screening
             period.

          -  Subject must be evaluated for active or latent TB (tuberculosis) infection by using a
             PPD skin test (Mantoux test), Booster test, chest x-ray and detailed review of
             subjetc´s medical history.

          -  Subjects to whom the doctor has decided to prescribe adalimumab, because of fulfilling
             the requirements for this treatment.

          -  Diagnosed with PsA according to CASPAR criteria.

          -  Axial disease according to radiological criteria (at least unilateral sacroilitis
             grade II) and spinal inflammatory symptoms.

          -  Disease duration of no less than 24 weeks

          -  Patients with peripheral involvement (mixed forms of APs) must have been taking MTX
             for at least 12 weeks before screening and at stable doses of 10 to 25 mg/week for 8
             weeks before screening, or salazopyrine up to 3 mg/daily, or cyclosporin 2mg/kg or
             leflunomide 20 mg daily in the same conditions as MTX.

          -  Patient's doses of NSAIDs and oral corticosteroids (≤ 10 mg/day of prednisone or
             equivalent) should have been kept stable for 4 weeks before screening.

        Exclusion Criteria:

          -  Contraindications for treatment with anti-TNF.

          -  Prior treatment with other TNF inhibitors or other investigational drugs during the
             last 30 days (etanercept 4 weeks, infliximab 8 weeks).

          -  Uncontrolled diabetes.

          -  Uncontrolled high blood pressure.

          -  Unstable ischemic heart disease.

          -  Congestive heart failure.

          -  Severe pulmonary disease.

          -  Chronic leg ulcer.

          -  History of cancer or malignant lymphoproliferative disease.

          -  Positive serology for Hepatitis B indicating active infection or positive serology for
             Hepatitis C.

          -  History of positive HIV status.

          -  Persistent, recurrent or severe infections requiring hospitalization or treatment with
             oral antibiotics within 14 days prior to enrollment.

          -  Previous diagnosis or signs highly indicative of central nervous system demyelinating
             diseases.

          -  Active tuberculosis, histoplasmosis or listeriosis.

          -  History or presence of confirmed blood dyscrasia.

          -  Female subjects who are pregnant or breast-feeding.

          -  History of clinically significant drug or alcohol abuse in the last year.

          -  Treatment with MTX, salazopyrine, ciclosporin or leflunomide initiated within the last
             4 weeks before the screening. Treatment with corticosteroids (&gt;10mg/day or equivalent
             or modified dose within the previous 4 weeks before screening). And patients where an
             intraarticular corticoid infiltration has been practised within the last 4 weeks
             before the screening will be excluded from the study.

          -  Treatment with more than one NSAID within the last 4 weeks before the screening.

          -  Patients treated with any DMARD different from MTX, cyclosporine, leflunomide and
             sulfasalazine.

          -  Dosage of concomitant MTX, cyclosporine, leflunomide and sulfasalazine must be stable
             during the study, otherwise it should be properly justified and recorded in the case
             report form.

          -  Patients treated with any analgesic different from acetominophen, NSAIDs, oxycodone,
             codeine, propoxyphene, tramadol, hydrocodone or combinations of these products or
             equivalents. The use of potent opioids is not permitted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco J. Blanco-Garcia, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Complejo Hospitalario Universitario A Coruna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Arquitecto Marcide-Novoa Santos</name>
      <address>
        <city>Ferrol</city>
        <state>A Coruna</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Comarcal Villajoyosa</name>
      <address>
        <city>Villajoyosa</city>
        <state>Alicante</state>
        <zip>03570</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Monte Naranco</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Bellvitge</name>
      <address>
        <city>L´Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Jerez</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cadiz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Doctor Negrin</name>
      <address>
        <city>Las Palmas</city>
        <state>Gran Canaria</state>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Insular de Las Palmas</name>
      <address>
        <city>Las Palmas</city>
        <state>Gran Canaria</state>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Meixoeiro</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36214</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruna</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Basurto</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcantara</name>
      <address>
        <city>Caceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Orense</name>
      <address>
        <city>Orense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <zip>36001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Donostia</name>
      <address>
        <city>San Sebastian</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2009</study_first_submitted>
  <study_first_submitted_qc>August 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2009</study_first_posted>
  <last_update_submitted>September 22, 2014</last_update_submitted>
  <last_update_submitted_qc>September 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Instituto de Investigacion Biomedica de A Coruna</investigator_affiliation>
    <investigator_full_name>Dr. FRANCISCO J. BLANCO-GARCIA</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Axial psoriatic arthritis</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>Humira</keyword>
  <keyword>anti-TNF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

